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It has been proposed that genomic instability is es-
sential to account for the multiplicity of mutations
often seen in malignancies. Using the X-linked PIG-A
gene as a sentinel gene for spontaneous inactivating
somatic mutations, we previously showed that
healthy individuals harbor granulocytes with the
PIG-A mutant (paroxysmal nocturnal hemoglobin-
uria) phenotype at a median frequency (f) of 12 
106. Herein, we used a similar approach to deter-
mine f in blast cells derived from 19 individuals with
acute lymphoblastic leukemia (ALL) and in immortal-
ized Epstein-Barr virus–transformed B-cell cultures
(human B-lymphoblastoid cell lines) from 19 healthy
donors. The B-lymphoblastoid cell lines exhibited a
unimodal distribution, with a median f value of 11 
106. In contrast, analysis of the f values for the ALL
samples revealed at least two distinct populations:
one population, representing approximately half of
the samples (n  10), had a median f value of 13 
106, and the remaining samples (n  9) had a me-
dian f value of 566  106. We conclude that in ALL,
there are two distinct phenotypes with respect to hy-
permutability, which we hypothesize will correlate
with the number of pathogenic mutations required to
produce the leukemia. (Am J Pathol 2012, 181:1862–1869
; http://dx.doi.org/10.1016/j.ajpath.2012.07.025)
For a few sentinel genes, such as HPRT,1,2, GPA3–5 XK,6HLA,7 and PIG-A,8 it is possible to use a phenotypic
1862screen to quantitate the frequency (f) of spontaneously
arising mutants in blood cells from healthy individuals. In
these models, f values generally range from 1  106 to
60  106, depending on the sentinel gene and the
age of the individual. Such estimates are critical for quan-
titative models of carcinogenesis. For example, consid-
ering that mutations in n different oncogenes or tumor
suppressor genes are required for the development of
malignancy, if each one were to occur independently,
then the probability of n mutations coinciding in the same
cell should approximate f n, where f represents the geo-
metric mean of the frequencies for the different onco-
genic mutations. Since the adult body has 1014 cells, it
has been argued that given these measured values for f,
it would be impossible for malignancy ever to occur if n
2 unless spontaneous mutation rates were to somehow
increase during the process of malignant transforma-
tion.9,10
Hypermutability could result from environmental mu-
tagenesis or from genetic or epigenetic inactivation of
repair genes. Abnormalities in the expression or fidelity
of DNA polymerases and/or DNA repair genes10,11
could also result in hypermutability. In support of this
model, results from cancer genome sequencing proj-
ects have generally demonstrated a surprisingly high
number of mutations.12–14 However, mutations in repair
genes or polymerases have not been commonly found.
An alternative model to account for the multiplicity of
mutations in cancer in the absence of hypermutability
would involve successive rounds of clonal selection.
Here, each oncogenic mutation would result in a partial
growth advantage in a dividing premalignant cell pop-
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AJP November 2012, Vol. 181, No. 5ulation. According to this model, we might not expect
to see a high frequency of phenotypic variants using a
sentinel gene that is not itself an oncogene or a tumor
suppressor gene.
To evaluate these models, we considered it important
to investigate whether there is evidence of hypermutabil-
ity in ex vivo leukemic blasts. However, in applying a
phenotypic screen for rare mutants in a leukemic blast
population, we are limited by three considerations: i) for
some of the sentinel genes mentioned previously herein
(eg, XK and GPA), mutants can be detected only in red
blood cells; ii) for HPRT, the cells must grow well in vitro,
which ex vivo blast cells do not readily do; and iii) for
autosomal genes, the effect of a loss of function mutation
on one chromosome may be complemented by the un-
mutated allele on the homologous chromosome. For a
few autosomal genes that have well-characterized poly-
morphic alleles (eg, HLA and GPA), it is possible to iden-
tify spontaneous loss of one allele—but only in cells from
certain individuals who have a specific compound het-
erozygote genotype.
PIG-A15 does not have these limitations and has sev-
eral advantages as a sentinel gene for spontaneous so-
matic mutations. Because PIG-A is X-linked (as are HPRT
and XK), a single inactivating mutation can produce the
mutant phenotype owing to lyonization in females and
hemizygosity in males. PIG-A has been well character-
ized owing to its association with paroxysmal nocturnal
hemoglobinuria (PNH), and it is known that a broad spec-
trum of mutations can inactivate the gene,16,17 providing
a model for the inactivation of tumor suppressor genes
and many of the point mutations that would activate on-
cogenes. We and others have demonstrated occult pop-
ulations of cells with the PIG-A mutant (PNH) phenotype
and genotype in diverse cell types, including granulo-
cytes,8 lymphocytes,18,19 human B-lymphoblastoid cell
lines (BLCLs),20,21 and marrow progenitors from normal
donors,22 as well as cell lines derived from neoplasms.23
Animals also harbor rare populations of spontaneously
arising blood cells with the PIG-A mutant phenotype, and
the frequency can be shown to increase as a result of
mutagen exposure, as recently reviewed.24
A further advantage of using PIG-A as a sentinel gene
is that its inactivation confers loss from the cell surface of
all proteins that require glycosylphosphatidylinositol
(GPI), resulting in a phenotype that can be detected by
flow cytometry without a requirement for in vitro cell
growth. PIG-A is widely expressed, and GPI is present in
diverse cell types, including primitive hematopoietic cells
such as leukemic blasts. In addition, antibodies specific
for more than one GPI-linked protein can be used simul-
taneously, along with the fluorescent aerolysin (FLAER)
reagent,25 which binds to the GPI structure directly, to
maximize the specificity of any assay. In a previous study
using PIG-A, we demonstrated hypermutability in many
but not all cell lines derived from hematologic malignan-
cies.26 Herein, we applied this approach to determine
whether hypermutability can be demonstrated in popula-
tions of blasts from patients with ALL.Materials and Methods
Frozen aliquots of de-identified ficol-sedimented marrow
samples were obtained from the Children’s Oncology
Group repository and from the NYU Department of Pa-
thology in accordance with institutional protocols. All the
samples analyzed were known to have been derived from
the initial diagnosis of leukemia, before the administration
of chemotherapy, except for the sample from patient 2,
which was de-identified in a way such that this informa-
tion was not available. As a control, samples of whole
blood were donated by patients with PNH, who provided
signed informed consent. Epstein-Barr virus–transformed
B-cell lines (BLCLs) were generated using Epstein-Barr
virus stock obtained from ATCC to infect lymphocytes
obtained from cord blood samples from discarded pla-
centas as well as whole blood from healthy adult donors
providing consent as per the Veterans Affairs Medical
Center and New York University Institutional Review
Board protocol. Six established BLCLs were obtained
directly from the Coriell Cell Repositories (Camden, NJ).
Figure 1. Flow cytometry pseudocolor dot plot analyses of controls. Fluo-
rescein isothiocyanate (FITC) and Alexa 488 register on FL1 (horizontal axis)
and reflect the density of the GPI-linked proteins (CD55 and CD59) and the
GPI anchor itself, respectively, on the surface of the cell. Phycoerythrin (PE)
registers on FL2 (vertical axis), reflecting the density of CD45, a non–GPI-
linked membrane protein. GPI cells register in the top left quadrant, and
GPI cells register in the top right quadrant. A: Peripheral blood lymphocytes
(PBLs) isolated from a patient with PNH. There are two distinct populations
representing GPI and GPI cells. B: A spontaneously arising GPI clone of
the Jurkat cell line registering in the top left quadrant. C: A representative
BLCL derived from a healthy donor (BLCL 12): most of the cells are GPI,
with a small but distinct subpopulation of GPI cells registering in the top left
quadrant. The frequency of these spontaneously arising phenotypic variants
6is 24  10 in this example. D: Unstained thawed blasts from a patient with
ALL.
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BLCLs started to grow and exhaust the media, cyclospo-
rine was added at a concentration of 2 g/mL to prevent
T-cell activation. The cells were then grown in RPMI 1640
medium with 15% fetal bovine serum, L-glutamine, peni-
cillin-streptomycin, and nonessential amino acids.
Samples from patients with ALL were first thawed and
diluted into Dulbecco’s modified Eagle’s medium media
with at least 20% fetal bovine serum and then were incu-
bated with the Alexa 488–conjugated FLAER reagent
(Pinewood Scientific Services Inc, Victoria, BC, Canada)
for 30 minutes at 37°C at a concentration of 5  107
mol/L. The cells were then placed on ice for the remain-
der of the experiment and then were incubated with
Figure 2. Flow cytometry pseudocolor dot plot analyses of samples derived
from ALL blast populations. A and B: Representative examples of samples
with a low frequency of spontaneously arising GPI phenotypic variants
(patients 7 and 17, respectively). C: An example of a sample with an inter-
mediate-sized population of GPI phenotypic variants (patient 11). D–F:
Representative examples of samples exhibiting a very high frequency of

Table 1. BLCL Controls from Healthy Donors
Cell line Sex
Age of donor
(years)
No
G
BLCL 1 F 77
BLCL 2 M 73
BLCL 3 M 29
BLCL 4 M 71
BLCL 5 NA NA
BLCL 6 NA Cord blood
BLCL 7 NA Cord blood
BLCL 8 NA Cord blood
BLCL 9 NA Cord blood
BLCL 10 M NA
BLCL 11 F 83
BLCL 12 F 60
BLCL 13 M 31
BLCL 14 (GM03299) F 8
BLCL 15 (GM03715) F 12
BLCL 16 (GM00130) M 25
BLCL 17 (GM14583) M 31
BLCL 18 (GM00131) F 23
BLCL 19 (GM14537) M 20
F, female; M, male; NA, not available.GPI phenotypic variants (patients 5, 14, and 19, respectively). FITC, fluo-
rescein isothiocyanate; PE, phycoerythrin.mouse anti-CD55 and anti-CD59 antibodies (1:20 dilu-
tion; AbD Serotec, Raleigh, NC). The cells were then
washed twice and incubated with fluorescein isothiocya-
nate–conjugated rabbit–anti-mouse immunoglobulin (1:5
dilution; Dako, Carpinteria, CA). The cells were washed
twice again, were incubated with phycoerythrin-conju-
Figure 3. Histogram of f values for BLCL and ALL samples. A: Using a 
value of 0.25 in a Box-Cox transformation, f values for the BLCLs are uni-
modal and nearly symmetrical, and they fall on a nearly straight line in a q-q
plot, suggesting that these values are near normally distributed. B: There is
no transformation that could produce a unimodal symmetrical distribution
ted
lls
Total No. of gated
cells
Frequency of GPI cells
per million (f  106)
1,329,700 27
1,319,757 8.3
1,240,805 11
1,165,695 149
1,091,817 0.9
750,602 4.0
396,746 0.0
663,771 7.5
884,288 62
504,941 16
789,240 30
1,041,825 24
738,969 11
1,882,614 3.2
1,411,330 12
1,671,951 105
1,342,490 2.2
1,642,549 6.7
1,450,815 15. of ga
PI ce
36
11
13
174
1
3
0
5
55
8
24
25
8
6
17
176
3
11
22for the f values measured in ALL samples. Using a log transformation of the
f values, it is seen that the distribution is bimodal or trimodal.
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were washed again. To ensure that the entire sample
population came in contact with the reagents, antibodies
were added to pelleted cells, which were resuspended,
briefly centrifuged, and then resuspended again at the
start of each incubation. Propidium iodide was added at
a concentration of 0.1 g/mL before analysis using a
FACScan flow cytometer (BD Biosciences, San Jose,
CA). As a control, using this protocol, we stained lympho-
cytes from a patient with PNH, BLCLs from healthy do-
nors, the T-cell leukemia line Jurkat, and a GPI subclone
of Jurkat that had been selected with proaerolysin. By this
approach, GPI cells appear in the top left quadrant and
GPI cells appear in the top right quadrant. Of note, the
emission spectrums of Alexa 488 and fluorescein isothio-
cyanate are extremely close, allowing for detection of
both fluorochromes together in a single channel (FL1).
When analyzing ALL blasts and control BLCLs from
healthy donors, we gated on cells based on forward and
side scatter, and we excluded dead cells, which take up
propidium iodide, which registers in FL3.
Voltage settings were applied to the photomultiplier
tubes such that unstained blast cells would exhibit mean
FL1 and FL2 values of 2.5 so that 80% of the un-
stained cells would exhibit FL1 values 5 (Figure 1D). In
studies of spontaneously arising GPI cell populations in
other cell types, we have found that after appropriate
fluorochrome compensation, GPI cells can be repro-
ducibly identified as having 4% of the fluorescence of
the wild-type population. We, therefore, defined GPI
cells as having 4% of the FL1 fluorescence of the wild-
type population; in cases where this value would be 5,
we used a value of 5 fluorescence units to define the
GPI cells based on the characteristics of unstained
blast cells. To exclude cells with a global defect in mem-
brane proteins, we gated on CD45 events, excluding
any cells with an FL2 fluorescence 10% of the mean of
the overall population, which allowed inclusion of
99.7% of the analyzed cells. To maximize the chances
of identifying rare events, we aimed to include at least 1
million gated events in each analysis. The frequency of
phenotypic variants was calculated as the number of live
CD45 GPI events divided by the total number of live
CD45 cells analyzed.
Results
As expected, analysis of peripheral blood lymphocytes
from a patient with PNH who was known to have a sub-
stantial PNH clone in the lymphocyte, granulocyte, and
red blood cell lineages revealed two distinct populations
with respect to expression of the GPI-linked proteins
CD55 and CD59 and uptake of the FLAER reagent (Fig-
ure 1A). Similarly, a GPI subclone of Jurkat registered in
the top left quadrant (Figure 1B), whereas the parental
Jurkat culture registered in the top right quadrant (data
not shown).
We then analyzed Epstein-Barr virus–immortalized
BLCLs from healthy donors. A representative example is
shown in Figure 1C, where most of the cells are seen toexpress GPI-linked proteins, take up the FLAER reagent,
and express the transmembrane protein CD45. Almost
the entire population, therefore, registers in the top right
quadrant. However, there are rare events in the upper left
quadrant that appear phenotypically identical to the con-
trol GPI cells in Figure 1, A and B. Twenty-five such
events were counted in 1,041,825 cells analyzed, and the
f value of these spontaneously arising GPI phenotypic
variants in this example is, therefore, 24  106.
In a panel of 19 BLCLs from healthy donors, a median
of 1.2 million gated events were analyzed (range, 0.4
million to 1.9 million). In all but one BLCL cell line, at least
one spontaneously appearing GPI event was identified
that registered in the top left quadrant. The mean fre-
quency of these phenotypic variants was 26 106, with
a median value of 11  106 and a range of 0 to 149 
106 (Table 1). Using a  value of 0.25 in a Box-Cox
transformation, this distribution of values was unimodal
and symmetrical, possibly with one high outlier, and the
transformed data plotted on a q-q plot demonstrated a
nearly straight line, suggesting a near normal distribution.
We also applied this analysis to ALL blasts (Figure 2).
Of the 25 available frozen samples, 6 had a lack of
viability, extensive cell clumping after thawing, insuffi-
cient cells for analysis, or a tail of the distribution curve
with respect to FL1 fluorescence that precluded discrim-
ination of GPI from GPI cells. In the remaining 19
cases (4 cases of T-cell ALL and 15 cases of B-lineage
ALL), it was possible to identify spontaneously arising
phenotypic variants. Looking at the f values, the distribu-
tion clearly differed from that of the values derived from
the analysis of BLCLs from healthy donors. Herein, the f
values spanned four orders of magnitude, ranging from
2.5  106 to 16,374  106. The mean value was
1046  106, and the median value was 65  106. The
f values for the ALL samples, overall, were significantly
higher than those for the BLCLs (P 0.03, 1-sided Mann-
Whitney U-test). In contrast to the distribution obtained for
the BLCLs (Figure 3A), using different possible  values
ranging from 1 to 1 in the Box-Cox formula, there was
no transformation that could produce a straight line on
the q-q plot or a histogram with a unimodal distribution
for the ALL samples (Figure 3B). The 10 ALL samples
with the lowest f values had a median f value of 13 
106. Representative samples with a low frequency of
GPI variants are shown in Figure 2, A and B. The re-
maining nine samples had a median f value of 566 
106. Representative samples with a high frequency of
phenotypic variants are shown in Figure 2, D–F. Using a
log transformation of the f values, it is seen that there are
at least two distinct populations (Figure 3B). In fact, the
distribution may be trimodal, and Figure 2C shows a
representative sample with an intermediate frequency of
phenotypic variants, in this case 88  106.
Discussion
We have taken advantage of the unique properties of the
PIG-A gene to develop a novel sensitive assay for the pres-
ence of phenotypic variants among leukemic blasts from
vailable
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synthesis of the GPI structure and the expression of GPI-
linked membrane proteins, the PIG-A mutant phenotype
can be detected by flow cytometry using monoclonal anti-
bodies against GPI-linked proteins together with FLAER, a
fluorescent reagent that binds to GPI directly. This ap-
proach allows for screening of a large number of cells to
identify rare, spontaneously arising phenotypic variants,
which is otherwise not possible to do. Herein we found two
distinct patterns. Approximately half of the samples we an-
alyzed exhibited a frequency of phenotypic variants similar
to results obtained from nonmalignant blood cells from
healthy donors. The other half of the samples we analyzed
demonstrated a high frequency of spontaneously arising
GPI cells, which is highly suggestive of genomic instability.
The simplest interpretation of these data is that there
are two different pathways to developing leukemia. In the
first case, a small number of mutations—perhaps only
one mutation in addition to a translocation13—are suffi-
cient to initiate the process of leukemogenesis. In this
case, hypermutability might not be necessary, and non-
oncogenic mutations in genes such as PIG-A will be rare,
with a frequency comparable with that of nonmalignant
cells. In the second pathway, a large number of onco-
genic mutations are required, which could most easily
occur as a result of genomic instability, which will be
reflected by an increased number of mutations in onco-
genes and an increase in nononcogenic mutations.27 In
this pathway, we would, therefore, expect an increased
frequency of GPI phenotypic variants. Individuals with
germline variations in repair genes resulting in constitu-
tional hypermutability20 and those with acquired repair
Table 2. Samples from Patients with Leukemia
Patient no./sex/
age (years)
WBCs
(103 per L) Lineage
1/M/41 NA B
2/F/13 NA T
3/M/18 NA T
4/M/4 NA B
5/M/15 4.5 B
6/F/4.5 8.6 B
7/F/7 2.8 B
8/M/3.5 38 B
9/F/6 588 T
10/M/3 18 B
11/M/9 1.9 B
12/F/4 5.8 B
13/M/11 4.8 T
14/F/2 63 B
15/F/5 23 B
16/M/4 13 B
17/M/3 53 B
18/F/19 9.3 B
19/M/17 3.9 B
F, female; M, male; FISH, fluorescence in situ hybridization; NA, not adefects occurring specifically in the cells of origin of themalignancy could achieve the requisite number of onco-
genic mutations through this second pathway.
It is possible that an initial oncogenic translocation will
determine whether the leukemia demonstrates a high or a
low mutator phenotype: for example, leukemias harbor-
ing the t(12;21) translocation resulting in the ETV6/RUNX1
(TEL-AML1) fusion have been shown to have a higher
number of deletion mutations than those with an MLL
translocation.13 Indeed, herein we found that four of five
of the samples harboring the ETV6/RUNX1 translocation
(patients 4, 6, 14, 15, and 19 in Table 2) demonstrated a
markedly elevated f value, as was the case for the sample
from patient 1, which harbored a BCR-ABL translocation.
The BCR-ABL translocation has recently been associated
with intratumoral genetic diversity,28 and a mechanism
has been proposed whereby the BCR-ABL fusion protein
directly results in oxidative stress and secondary muta-
tions.29 Two of the samples we analyzed were consid-
ered to be hyperdiploid based on trisomies of chromo-
somes 4 and 10 (patients 13 and 18), and both of these
had a low f value. We believe that with a large number of
samples, each harboring the same cytogenetic abnor-
mality, we may be able to investigate the biological fac-
tors associated with hypermutability using this method.
We believe that an elevation in f, as detected in this
assay, is due to an increase in the mutation rate rather
than increased cell turnover. In a previous work using cell
lines, we were able to control for cell divisions, measure
the mutation rate directly, and demonstrate that it is fre-
quently, but not universally, elevated in hematologic ma-
lignancies.26 We recently analyzed the mutation rate in a
panel of cell lines derived from Burkitt neoplasms and
Metaphase cytogenetics
BCR-ABL
(FISH)
Positive
NA
q;18q) Negative
NA
Negative
Negative
Negative
Y,5[16]/46,XY[4] Negative
XX [40] Negative
X,X,4,14,17,21,21[8]/46,XY[4] Negative
Negative
XX[20] Negative
87,XXYY,4,11,15,21[CP18]/46,XY[2] Negative
Negative
XX[14] Negative
Negative
Y,X,DUP(1)(q21q42),10,14,17,21,
21[4]/53,IDEM,3[4]
Negative
X,X,4,6,8,9,10,11,14,14,
ER(16) t(11;16)(q21;q22),ADD(17)(p12),
18,21,21[17]/46,XX[2]
Negative
Y,t(4;11)(q27;q24),DEL(6)(q21),t(13;14)
32;q13),ADD(15)(q26)[4]/46,XY[6]
Negative
(table continues)
; WBC, white blood cell.NA
NA
t(13
NA
NA
NA
NA
47,X
46,
52,X
NA
46,
85
NA
46,
NA
52,X

58,X
D

46,X
(qfound that the distribution of mutation rates in this type of
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tion). In studying ALL, we cannot control for cell divisions
because ex vivo leukemic cells do not often adapt to
tissue culture. However, the control cells, the BLCLs, had
been growing well in culture for a median of 5 months
before they were analyzed. These BLCLs did not dem-
onstrate any increase in f compared with f values from
previous work in granulocytes8 or estimates of f using
other model systems.1–7,20,30,31 Indeed, although they
were growing rapidly in vitro, their f values overall were
significantly lower than those of the ALL samples, sug-
gesting that hypermutability in a subgroup of ALL sam-
ples is likely to be a feature of the malignant phenotype
rather than of proliferation per se.
The assay is set up to detect mutations in the PIG-A
gene, which can be inactivated by a broad spectrum of
mutations,16,17 including nonsense, missense, and splice
site mutations; frameshifts; small in-frame deletions; and
very large deletions. Although in PNH the GPI pheno-
type, as a rule, results from mutations in PIG-A, strictly
speaking, the GPI phenotype could be produced by
loss (or epigenetic silencing32) of any of the 20 genes
involved in GPI anchor synthesis33–35 or the genes nec-
essary for GPI trafficking.36 However, except for PIG-A,
these genes are autosomal34 and would probably require
biallelic inactivation to produce the GPI phenotype,
which would probably occur less frequently than a single
PIG-A mutation.
We cannot completely rule out the possibility that the
GPI phenotype could be positively or negatively se-
lected at various stages in the development of leukemia,
which could increase or decrease, respectively, the f
Table 2. Continued
MLL
(FISH)
Trisomy
4 and 10
(FISH)
ETV6/RUNX1
(FISH)
Hypo
(FI
NA NA NA N
NA NA NA N
NA NA NA N
NA NA Positive N
Negative Negative Negative N
Negative NA Positive N
Negative Negative Negative N
Negative Negative Negative N
Negative Negative Negative N
Negative Negative Negative N
Negative Negative Negative N
Negative Negative Negative N
Negative Positive Negative N
Negative Negative Positive N
Negative Negative Positive N
Negative Negative Negative N
Negative Negative Negative N
Negative Positive Negative N
Negative Negative Positive Nvalues we observe. However, it is widely believed thatPIG-A mutations are growth neutral in vivo and in
vitro20,37–39 in situations apart from the special case of
aplastic anemia.40 Of note, PIG-A is not emerging as a
driver gene in genome-wide analyses,12,41–46 arguing
that selection in favor of PIG-A mutants is an unlikely
explanation for these findings. Although it is highly likely
that an increase in the frequency of phenotypic variants
as measured herein is due to genomic or epigenetic
instability, we cannot say that a low f value rules out all
forms of hypermutability. Specifically, a propensity to-
ward translocations and gene amplifications would prob-
ably escape detection here. In addition, theoretically, it is
possible that successive rounds of clonal selection could
periodically reduce the observed frequency of pheno-
typic variants, as has been reported in yeast growing in
culture over a prolonged period.47
Another caveat is that we cannot be certain that PIG-A
is reflective of the mutation rate in other genes. This is an
issue any time a sentinel gene is chosen, particularly
because a phenotypic screen is possible for only a very
few genes for comparison. Of note, our studies on the
mutation rate in nonmalignant human cells using PIG-A
have generally corresponded to mathematical models of
the mutation rate in HPRT.20 Although it is possible to
perform deep sequencing for a large number of genes to
demonstrate intratumoral diversity, in a recent study us-
ing this technology,48 this approach had a sensitivity of
detecting a heterozygous point mutation of 1 per 166
cells, below which mutations could not be distinguished
from sequencing errors. Random mutation capture is a
highly sensitive assay developed by Bielas et al27 to
detect rare point mutations at recognition sites for a
No. of
gated GPI
cells
Total no. of
gated cells
Frequency of GPI
cells per million
(f  106)
510 1,844,838 276
16 331,368 48
49 1,618,408 30
148 244,609 605
579 1,022,860 566
13 749,933 17
6 1,057,166 5.7
133 2,059,699 65
83 983,522 84
2 787,833 2.5
62 708,410 88
200 1,196,416 167
24 1,242,719 19
635 811,457 783
1053 1,438,327 732
8 1,917,780 4.2
12 2,200,433 5.5
2 220,314 9.1
1791 109,384 16,374diploid
SH)
A
A
A
A
o
o
o
o
o
o
o
o
o
o
o
o
o
o
ohighly efficient restriction enzyme and, in the future, may
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dom mutation capture is unlikely to be as easily imple-
mented as an assay based on flow cytometry.
Despite these caveats, we believe that we have devel-
oped the first clinically applicable test that is reflective of
hypermutability and tumoral genetic diversity in leukemic
blasts, and we believe that the parameter we measured
herein is likely to be clinically relevant. For example, a
high f value might correlate with the probability of muta-
tions in genes associated with relapse and chemother-
apy resistance,45,49 and, indeed, mutations in PIG-A itself
could confer resistance to alemtuzumab, which targets
CD52, a GPI-linked protein.18 In fact, there are recent
data from an animal model of human ALL that this may
occur.50 Conversely, leukemias that demonstrate hyper-
mutability may be more susceptible to the effects of DNA-
damaging drugs, such as alkylating agents and anthra-
cyclines, that might increase the mutation rate above the
threshold at which viability would be compromised.
These findings suggest that it will be possible to apply
this analysis at the time of routine phenotyping of leuke-
mia and to investigate these questions further by follow-
ing patient outcomes prospectively.
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